Orforglipron: the second oral GLP-1 agonist [keto chews keto acv gummies]

Orforglipron: the second oral GLP-1 agonist [keto chews keto acv gummies]

| 1h 28m 28s | Video has closed captioning.

🔷 DEA and Cannabis: What’s Happening Now? ✅ Proposal to Reschedule Cannabis In 2024, the Department of Health and Human Services (HHS) recommended that the DEA reschedule cannabis from Schedule 1 to Schedule 3 under the Controlled Substances Act (CSA). Schedule 1 includes drugs like heroin and LSD — substances deemed to have no accepted medical use and a high potential for abuse. Schedule 3 includes drugs like ketamine and anabolic steroids — recognized for medical uses and considered to have moderate abuse potential. ⸻ 🏛️ What Rescheduling Would Mean If the DEA finalizes rescheduling cannabis to Schedule III: 🔬 Research Access Improves Researchers would face fewer regulatory barriers. Easier to study medical benefits and risks of cannabis. 💊 Medical Legitimacy Acknowledges that cannabis has accepted medical uses. Could pave the way for FDA-approved cannabis-based therapies. 📈 Business and Tax Changes • Cannabis businesses could potentially: • Deduct expenses under IRS tax code (280E no longer applies to Schedule 3 substances). • Access more financial services, though many federal banking issues would remain. 🚫 Still Not Legal for Adult Use Federally Recreational use would remain federally illegal, even if rescheduled. States’ legalization laws would still conflict with federal law — although enforcement has largely been hands-off in legal states. ⸻ ❗ Key Limits of Rescheduling It would not automatically legalize state-licensed cannabis businesses at the federal level. Still doesn’t allow interstate commerce of cannabis products. Cannabis possession would still be federally criminalized outside medical or research contexts. ⸻ 🔍 Current DEA Process (As of May 2025) DEA is conducting a scientific and regulatory review following HHS’s recommendation. No official final rule yet, but widespread reporting suggests the DEA may agree with reclassification. The final decision will include a public comment period, and may be challenged legally by opponents or supporters. ⸻ 🧭 What Comes Next? If DEA reschedules cannabis: Expect rules for pharmaceutical-style regulation to develop. The move may encourage Congress to pass broader reform (e.g., the STATES Act or federal legalization bills). If DEA rejects the recommendation, political pressure is expected to intensify.